权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Predictive Networks-based in-silico approach for Precision Medicine-repurposing for Alzheimer's Disease

基于预测网络的精密医学方法 - 重新利用阿尔茨海默病

基本信息

批准号：
10017130
负责人：
Rui Chang
金额：
$ 77.77万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-15 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10017130
关键词：
Affect Aftercare Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease pathology Amyloid beta-Protein Apolipoprotein E Astrocytes Behavior Binding Bioinformatics CASP3 gene Cell model Cells Cleaved cell Clinic Clinical Clinical Data Coculture Techniques Cognition Data Data Set Databases Dementia Disease Docking Drug Combinations Drug Screening Drug Targeting Drug toxicity Drug usage Endothelium Evaluation F Factor FDA approved Genetic Genomics Genotype Goals Human Cell Line Image In Vitro Investigation Investments Lead Measures Messenger RNA Microglia Modeling Mus Network-based Neurons Oligodendroglia Pathogenesis Pathogenicity Pathologic Pathway interactions Patients Peptides Pharmaceutical Preparations Process Proteins Proteomics Risk Risk Factors Safety Subgroup Systems Biology Testing Therapeutic Toxic effect Treatment Efficacy cell type cost efficient drug development drug efficacy genomic data in silico in vivo in vivo Model interest metabolomics model design mouse model multiple omics network models neuron apoptosis novel patient stratification patient subsets personalized approach precision drugs precision medicine recruit screening sex tau Proteins tau-1 therapeutic target therapy development trait transcriptome sequencing uptake whole genome

项目摘要

Project Summary Alzheimer's disease is the most common form of Dementia estimated to affect 36 million people worldwide. This number is expected to rise to 115 million by 2050 unless an effective therapeutic is developed. Recently, NIA organized large-scale efforts, through AMP-/M2OVE-AD consortia, has generated the richest genotype, genomic and clinical data, which enabled an unprecedented opportunity to explore the enormous complexity of AD pathogenesis. On the other hand, through all failed clinic trials, we learned that an efficacious treatment would need to target multiple aspects of the disease and be directed towards several pathogenic processes in AD. Moreover, patients with different sex and risk factor will respond differently to the same treatment due to distinct pathological mechanisms, therefore, it became extremely critical to develop patient-specific therapeutic targets and precision medicine for each patient sub-group. However, despite tremendous interests in advancing therapy and drug development for AD, there is a paucity of advanced bioinformatics approaches available to guide the effective and efficient development of drugs and de-risk investment in these expensive therapeutic approaches. We respond to the PAR (PAR-17-032) with the goals 1) to apply novel computational systems biology approach, i.e. top-down and bottom-up predictive network for short), to analyze the existing rich genetics, genomics, proteomics, metabolomics, and clinical datasets in AMP-AD and other datasets in AD and 2) to build network models and to predict therapeutic targets of single-cell type and multi-cell cross-talk pathways contributing to the onset and progression of AD pathology; 3) to stratify patients into sub-groups according to Sex, APOE and disease-stage (whenever clinical data available) and to predict therapeutic targets for each sub-group of patients towards precision medicine (drug repurposing) in AD; 4) to use novel in- silico prediction pipeline to prioritize therapeutic targets; 5) to repurpose FDA-approved, investigational, and experimental drugs binding to prioritized therapeutic targets through (known) on-targets and/or (predicted by docking) off-targets; 6) to in-silico evaluate repurposed drugs: efficacy, toxicity, mechanism, transability through BBB; 7) to evaluate prioritized drug/combination using in-vitro and in-vivo AD models.

项目总结